New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
09:05 EDTGLYC, PFEGlycoMimetics announces agreement with FDA for rivipansel
GlycoMimetics (GLYC) announced today that Pfizer (PFE) has reached agreement with the U.S. Food & Drug Administration under a special protocol assessment for a Phase 3 trial for rivipansel. A SPA is a written agreement between a trial’s sponsor and the FDA regarding the design, endpoints and statistical analysis approach of a Phase 3 clinical trial, results from which could potentially support approval of a New Drug Application. Rivipansel is being developed as a potential therapy for treatment of patients with sickle cell disease who are hospitalized for vaso-occlusive crisis. Rivipansel has previously received both Orphan Drug and Fast Track status for the treatment of VOC from the FDA. Pfizer plans to begin the Phase 3 program before the end of 2014.
News For GLYC;PFE From The Last 14 Days
Check below for free stories on GLYC;PFE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
07:43 EDTPFEBofA/Merrill to hold a conference
Subscribe for More Information
September 16, 2014
11:51 EDTPFEOECD looks to close tax loopholes with new proposals
Subscribe for More Information
07:19 EDTPFECompanies' share buybacks at fasttest clip since 2007, WSJ reports
Companies are buying back their own shares at its fastest pace since the financial crisis to fuel a stock rally, reports the Wall Street Journal. According to Birinyi Associates, companies have bought back $338.3B of stock in 1H14, the most since 2007. Citing an analysis by Barclays, companies with the largest buyback programs by dollar value have outperformed the broader market by 20% since 2008. Reference Link
September 15, 2014
09:25 EDTPFEJPMorgan biotech analysts hold an analyst/industry conference call
Analysts assess Pfizer's M&A options on an Analyst/Industry conference call to be held on September 15 at 10 am.
07:27 EDTPFEIBC Life Sciences to hold a conference
Subscribe for More Information
07:27 EDTPFEPfizer acquisition could drive shares higher, says JPMorgan
Subscribe for More Information
September 14, 2014
13:32 EDTPFEPfizer shares look cheap, Barron's says
Subscribe for More Information
September 12, 2014
10:32 EDTPFEPfizer CEO says company still open to inversion deal, FT says
Pfizer (PFE) CEO Ian Read said U.S. rhetoric against tax inversions has been "political theater" ahead of midterm elections and made clear that his company is still open to a potential tax-saving acquisition, according to Financial Times, which added Read's comment about not being “held hostage” over price would likely be read as a signal the company might look elsewhere after being rebuffed by AstraZeneca (AZN). The Fly notes that Bloomberg previously reported, citing people familiar with the matter, that Pfizer is looking at targets other than AstraZeneca, including Actavis (ACT). Shares of Actavis trading in New York are up 2% this morning. Reference Link
September 8, 2014
16:03 EDTGLYCGlycoMimetics to present poster on in vivo efficacy of GMI-1051
Subscribe for More Information
07:15 EDTPFEIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.
September 4, 2014
16:05 EDTPFEPfizer granted orphan status for sickle cell disease drug
Subscribe for More Information
07:23 EDTPFEAstraZeneca called for inversion clamp down as part of defense, WSJ says
Amid its defense against an unsolicited takeover bid from rival Pfizer (PFE), AstraZeneca (AZN) hired advisers with close ties to the Obama administration, who made calls to senior administration officials urging a clamp down on tax inversions, said The Wall Street Journal, citing people familiar with the previously undisclosed calls. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use